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Abstract: 2-(2’,4’-Dibromophenoxy)-4,6-dibromophenol isolated from the marine sponge 
Dysidea granulosa (Bergquist) collected off the coast of Lakshadweep islands, Indian 
Ocean, exhibited potent and broad spectrum in-vitro antibacterial activity, especially 
against methicillin resistant Staphylococcus aureus (MRSA), methicillin sensitive 
Staphylococcus aureus (MSSA), vancomycin resistant Enterococci (VRE), vancomycin 
sensitive Enterococci (VSE) and Bacillus spp. Minimal inhibitory concentration (MIC) 
was evaluated against 57 clinical and standard strains of Gram positive and Gram negative 
bacteria. The observed MIC range was 0.117-2.5 μg/mL against all the Gram positive 
bacteria and 0.5-2 μg/mL against Gram negative bacteria. The in-vitro antibacterial activity 
observed was better than that of the standard antibiotic linezolid, a marketed anti-MRSA 
drug. The results establish 2-(2’,4’-dibromophenoxy)-4,6-dibromophenol, as a potential 
lead molecule for anti-MRSA and anti-VRE drug development. 
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1. Introduction  
 
The striking rise in the prevalence of bacterial antibiotic resistance currently poses a serious threat 
to public health worldwide. Of particular concern are infections caused by methicillin-resistant 
Staphylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumoniae, vancomycin-resistant 
Enterococcus
  [1] and Mycobacterium tuberculosis
  [2]. Many of these organisms have developed 
resistance to several classes of established antibiotics [1,2]. The most significant problem in clinical 
practice is the increase in incidence of MRSA infections. At present, the only effective treatment for 
multiple resistant MRSA infections is vancomycin. However, there are number of reports of emerging 
vancomycin resistance in some MRSA isolates [3]. Another group of clinically relevant multiple drug 
resistant bacteria that has emerged recently are Enterococci, some of which also exhibit vancomycin 
resistance. The appearance of vancomycin resistant Enterococci (VRE) infections has caused a 
dilemma upon physicians – linezolid and streptogramin combinations are the new drugs of choice for 
treating MRSA infections, but linezolid resistance have been reported in VRE and MRSA isolates [4]. 
Resistance to these oxazolidinone [5] streptogramin combinations [6,7]
 and various glycopeptides [5] 
requires expanded development of agents with alternative targets or modes of action. Staphylococcus 
aureus is the most clinically important of the Gram positive pathogens because of its exceptional 
virulence, stress tolerance, and capacity to accumulate antimicrobial resistances. MRSA is known as a 
major nosocomial pathogen which has also developed resistance to many other antibiotics. Moreover, 
MRSA and other S. aureus strains have been reported to acquire resistance to the last-resort antibiotic, 
vancomycin [8,9]. These facts suggest that S. aureus (MRSA) could fully acquire resistance to 
vancomycin in the near future.  
The emergence and spread of resistant nosocomial and community-acquired pathogens is becoming 
a great menace to global public health. Therefore, a need is perceived to find new classes of 
antimicrobials. The search for new pharmacologically active agents obtained by screening natural 
sources has led to the discovery of many clinically useful drugs that play a major role in the treatment 
of human diseases. Approximately 60% of the antitumor and anti-infective agents that are 
commercially available or in late stages of clinical trials today are of natural product origin. Natural 
products are still major sources of innovative therapeutic agents for infectious diseases (both bacterial 
and fungal), cancer, lipid disorders and immunomodulation [10,11]. 
Given the diverse array of bioactive secondary metabolite chemical structures with a wide variety 
of biological activities isolated from marine sponges, natural product chemists have long been 
fascinated by these sessile marine invertebrates [11].
 One of the most extensively studied species of 
sponge is the tropical marine sponge Dysidea sp.  (family  Dysideidae, Order Dendroceratida), a 
pinkish green sponge that occurs in a number of distinct chemotypes as a result of an association with 
symbiotic microorganisms. The chemistry reported from this sponge and related sponges in the genus, 
includes sesquiterpene spirolactol/lactones,
  tricyclic furans,
  some based on the furodysinin and Mar. Drugs 2009, 7                             
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furodysin skeletons and their oxidised derivatives, modified steroids,
  polychlorinated alkaloids,
 
brominated diphenyl ethers and other metabolites. The polychlorinated alkaloids and brominated 
diphenyl ethers produced by the sponge have been shown to be associated with the filamentous 
cyanobacterium Oscillatoria spongeliae, and are therefore likely synthesized by the cyanobacterial 
symbionts [12–15]. 
Most halogenated phenols are found to be strongly antimicrobial. As a group, the halogenated 
bis(hydroxyphenyl) methanes and polybrominated diphenyl ethers exhibit a wide range of activities in 
bioassays, ranging from antibacterial activity (against S. aureus and T. mentagrophytes), to 
cytotoxicity (Ehrlich ascite tumor cells) [16,17]. Polybrominated biphenyl ethers from Dysidea 
herbacea are found to be active against eubacteria, as well as test strains of the unicellular marine 
cyanobacterium  Synechococcus  sp. [15]. Herein we have reported the isolation of   
2-(2’,4’-dibromophenoxy)-4,6-dibromophenol from a new source D. granulosa, its potent in-vitro 
antibacterial activity, and as a possible lead molecule for drug development especially against strains 
of MRSA, methicillin sensitive S. aureus (MSSA), VRE and vancomycin sensitive Enterococci (VSE). 
 
2. Results and Discussion 
 
In the course of our programme of screening for new compounds from marine resources,   
2-(2’,4’-dibromophenoxy)-4,6-dibromophenol was obtained from the sponge Dysidea granulosa as a 
colourless optically inactive crystalline solid, mp 179 
oC. It showed a max. UV-Vis (MeOH) 
absorbance at 340 nm. IR (KBr) showed major peaks at 3,492.8 (phenolic O-H str), 3,084.0 (aromatic 
C-H str), 1,591.5 (aromatic C=C str), 1,463.9(C-H bend), 1,147.6, 1039.6 (C-O str), 918.1, 869.8, and 
719.4 cm
-1 (C-Br str). Spectral data including 
1H-NMR (300 MHz, CDCl3), 
13C-NMR, COSY, HMQC 
and HMBC of the compound is given in Table 1. 
 
Table 1. 
1H-, 
13C-NMR, COSY and HMBC of 2-(2’,4’-dibromophenoxy)-4,6-dibromophenol. 
Carbon No. 
13C-NMR 
δC, ppm 
1H-NMR 
δH, ppm 
COSY 
correlations 
HMBC 
correlations 
1 138.6  -     
2 150.3  -     
3  119.7  7.20 (d, 2.3Hz)    1, 2, 5 
4 117.3  -     
5  127.8  7.34 (d, 2.3Hz)    4, 6 
6 119.8  -     
1’ 152.0  -     
2’ 112.6  -     
3’  136.2  7.77 (d, 2.3Hz)    1’, 5’ 
4’ 116.0  -     
5’  131.5  7.29 (dd, 8.8Hz)  H6’  3’, 1’ 
6’  115.9  6.43 (d, 8.8Hz)  H5’  1’, 2’ 
 
A quasimolecular [M-H]
- ion peak was observed at m/z 500.7023 (calculated: 500.6982); the 
corresponding [2M-2H]
- peak was observed at m/z 1001.7274 (calculated: 1001.3964). The mass Mar. Drugs 2009, 7                             
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spectral fragmentation pattern with the respective spectral peaks at [M-H]
- at 496.7042, 498.7054, 
500.7023, 502.7010 and 504.6974 (observed) and 496.7023, 498.7003, 500.6982, 502.6962 and 
504.6942 (calculated) in the ratio 17.30:68.0:100.0:65.70:16.50 was indicative of the presence of four 
bromine atoms.  
 
Figure1. Structure of 2-(2’,4’-dibromophenoxy)-4,6-dibromophenol. 
 
 
 
 
 
 
 
These spectral data were in good agreement with the spectral data reported in literature [15,18]. The 
two dimensional NMR data is reported here for the first time. 2-(2’,4’-Dibromophenoxy)-4,6-
dibromophenol was observed to be a potent inhibitor of the growth of clinically relevant Gram positive 
bacteria, especially MRSA and VRE. Preliminary testing by the agar diffusion method revealed that 
the compound is strongly antibacterial, but has no inhibitory effect against fungal strains. To evaluate 
its  in-vitro antibacterial potency and characterize its activity spectrum, the compound was tested 
against 57 bacterial test strains. The efficacy is measured in terms of minimum inhibitory 
concentration (MIC) and expressed in µg/mL. 
The spectrum of bacterial test cultures includes 20 clinically derived and 10 standard strains of 
MRSA, two standard strains of MSSA; 11 clinical strains of VRE, four standard strains of VRE, five 
standard strains of VSE; one each standard strains of E. coli, K. pneumoniae, S. typhi, S. flexneri and 
P. aeruginosa, including three methicillin resistant strains of S. aureus 3066, E710, ATCC 33591 and 
two vancomycin resistant strains of E. faecium 02 D3 IP1, R-2 and one vancomycin resistant strain of 
E. faecalis ATCC 51299, which were subjected to antibacterial activity tests.  
The compound showed potent, broad-spectrum in-vitro Gram-positive activity, as evident from 
Table 2. The compound exhibited no cross-resistance to other key antibiotics, which was evident from 
its potent activity against key antibiotic-resistant bacteria including MRSA, erythromycin-resistant  
S. aureus, and VRE (Table 3). Escherichia coli and Pseudomonas sp. were the least susceptible, with 
MIC values above 15 µg/mL (Table 2). However it was active against other Gram negative bacteria 
such as Klebsiella pneumonia, Shigella flexneri and Salmonella typhi (Table 2). The bromoether was 
tested by the agar diffusion assay against C. albicans, A. fumigatus, C. tropicalis, C. glabrata and was 
found to be inactive against fungi even up to 100 µg/mL. Thus, the compound specifically shows 
antibacterial activity. Our work has first time revealed the wide spectrum of activity of this compound. 
Its activity with variety of resistant strains confirmed that 2-(2’,4’-dibromophenoxy)-4,6-
dibromophenol did not show cross resistance with widely marketed antibiotics such as erythromycin, 
β-lactams, vancomycin, teichoplanin, gentamicin and streptomycin. Thus it reflects that the type of 
bacterial strains used for antibacterial efficacy testing has no resistance to this compound. Therefore it 
could be a potential molecule to develop further to address the resistance issue. 
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Table 2. Antimicrobial activity of 2-(2’,4’-dibromophenoxy)-4,6-dibromophenol. 
Test Organisms 
MIC Range 
(μg/mL) 
MIC50 
(μg/mL) 
MIC90 
(μg/mL) 
S. aureus* MRSA (20)  0.313-1.25  0.313  0.625 
S. aureus** MRSA (10)  0.313-10  0.313  0.625 
S. aureus** MSSA (2)  0.117-0.313  -  - 
Enterococci* VRE (11)  0.625-2.5  0.625  1.25 
E. faecalis** VSE (4)  1.25-2.5  -  - 
E. faecium** VSE (1)  1.25  -  - 
E. faecium** VRE (3)  1.25  -  - 
E. faecalis** VRE (1)  1.25  -  - 
E. coli** (1)  >15  -  - 
K. pneumoniae** (1)  2  -  - 
Salmonella typhi** (1)  0.5  -  - 
Shigella flexneri Type IV** (1)  2  -  - 
P. aeruginosa** M-35 (1)  >15  -  - 
*: Clinical derived strains, **: Standard strains procured from culture banks. -: Not applicable. 
#: The numbers in brackets indicate the no. of strains tested. 
 
Table 3. Antimicrobial activity of 2-(2’,4’-dibromophenoxy)-4,6-dibromophenol and 
linezolid towards resistant strains. 
 
3. Conclusions 
 
This is the first report of 2-(2’,4’-dibromophenoxy)-4, 6-dibromophenol from the sponge Dysidea 
granulosa and the first attempt to exhaustively test the in-vitro activity of this molecule. Results 
obtained indicate that the compound shows good lead properties for antibacterial drug development 
and represent a promising agent for the treatment of S. aureus as well as enterococcal infections 
caused by drug-resistant strains. 
 
4. Experimental Section  
 
4.1. General Experimental Procedures 
 
Column chromatography was carried out on silica gel 60-120 mesh, Sisco, India. Gel filtration on 
Sephadex LH20, Pharmacia Biotech, Sweden. Fractions were monitored on TLC kieselgel 60 F254 
Test organisms 
MIC (µg/mL) 
Compound Linezolid 
S. aureus (3066), MRSA, Ery
R 0.313  0.313 
S. aureus (E710), MRSA, Ery
R 0.625  2.5 
S. aureus ATCC 33591, MRSA  0.313  2.5 
E. faecium (02 D3 IP1), Vanco
R, Teicho
R 1.25  2.5 
E. faecium (R-2), Vanco
R (VanA)  1.25  2.5 
E. faecalis ATCC 51299, VRE, Gen
R, Strept
R (VanB) 2.5  2.5 Mar. Drugs 2009, 7                             
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aluminum backed sheets and visualized under UV (254 nm) and iodine vapors. UV-VIS spectrum was 
recorded in methanol using a Shimadzu UV-2401PC spectrophotometer. IR spectrum was recorded on 
a Shimadzu FTIR-8201 PC spectrophotometer. NMR spectra (
1H, 
13C, COSY, HMQC and HMBC) 
were recorded on a Bruker Avance 300MHz instrument. Chemical shifts, relative to TMS as internal 
standard, are given in δ values. J values are given in Hz. Mass spectra were obtained on a QSTAR XL 
MS/MS system.  
 
4.2. Collection of Animal Material and Chromatography 
 
The sponge was collected off the coast of Lakshadweep Islands by scuba diving at a depth of about 
8-10 meters and identified by Dr. P.A. Thomas of the Vizhingam Research Center of the Central 
Marine Fisheries Research Institute, Kerala, India. A voucher specimen is deposited at the National 
Institute of Oceanography, Dona Paula, Goa, India. The frozen sample of D. granulosa was 
lyophilized to obtain 200 g of dried sample, which was extracted successively with ethyl acetate and 
methanol (200 mL × 3 times each). These extracts were concentrated under reduced pressure and 
temperature to obtain the crude extracts. The ethyl acetate extract exhibited antimicrobial activity 
against pathogenic strains and was chromatographed over Sephadex LH20 (1:1 methanol-chloroform). 
Fractions that were similar in composition as shown by thin-layer chromatography were combined. 
The partially purified sample was further purified over silica gel (60–120 mesh) (2% ethyl acetate-
petroleum ether) to afford the single major polybrominated secondary metabolite   
2-(2’,4’-dibromophenoxy)- 4, 6-dibromophenol.  
 
4.3. Antimicrobial Activity 
 
Minimum Inhibitory Concentration (MIC) values were determined in Mueller Hinton Broth by the 
broth macrodilution method according to NCCLS guidelines, as per document no. M7-A5 [19]. The 
medium with a twofold serial dilution of compound in Mueller Hinton broth was inoculated with  
10
5 colony forming units/mL of test culture and incubated at 37 °C for 24 hrs. The MIC of the 
bromoether was determined against 57 test organisms including different clinical and standard strains 
of S. aureus, both MRSA and MSSA, clinical and inhouse strains of Enterococci, both VRE and VSE 
and some gram negative strains. American type culture collection (ATCC) strains were also screened. 
Linezolid (Glenmark Pharmaceuticals Ltd, India) was used as control agent. 
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